Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 9/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | BRS3 | P32247 | 1/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12561747 | 0.98 | AOC3 (0.50) | AOC3MAPTALDH1A1LMNAALOX12 | |
| SCHEMBL18924316 | 0.86 | HTR3A (0.45) | AOC3CYP11B1CYP11B2 | |
| SCHEMBL21934609 | 0.84 | CYP11B1 (0.41) | AOC3MAPTALDH1A1CYP11B1CYP11B2 | |
| SCHEMBL14903597 | 0.84 | CYP11B1 (0.60) | AOC3MAPTALDH1A1LMNACNR2 | |
| SCHEMBL21933955 | 0.82 | HRH3 (0.48) | AOC3CYP11B1CYP11B2 | |
| SCHEMBL8429477 | 0.81 | CYP1A2 (0.54) | AOC3MAPTALDH1A1LMNAALOX12 | |
| SCHEMBL9908392 | 0.80 | HRH3 (0.53) | AOC3MAPTALDH1A1LMNAALOX12 | |
| SCHEMBL345328 | 0.79 | PTPN11 (0.42) | AOC3MAPTLMNACYP11B1CYP11B2 | |
| SCHEMBL987818 | 0.78 | AOC3 (0.55) | AOC3MAPTALDH1A1LMNAALOX12 | |
| SCHEMBL10254758 | 0.78 | AOC3 (0.55) | AOC3MAPTALDH1A1LMNAALOX12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10189826-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2019-01-29 | — | — | US | disclosed |
| US-10183015-B2 | Heterocyclic compounds and methods of use | MEDIVATION TECHNOLOGIES LLC (US) | 2019-01-22 | — | — | US | disclosed |
| US-20180051013-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-02-22 | — | — | US | disclosed |
| US-20180028518-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES LLC | 2018-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180028518-A1 | Heterocyclic Compounds and Methods of Use | LIPC, CPT1A, FABP1 | AOC3 2401/4885MAPT 4172/4885ALDH1A1 779/4885 |
| US-10189826-B2 | Heterocyclic compounds and methods of use | HRAS, VHL, ESRRB | AOC3 3646/4885MAPT 4672/4885ALDH1A1 2384/4885 |
| US-10183015-B2 | Heterocyclic compounds and methods of use | LIPC, CPT1A, FABP1 | AOC3 2401/4885MAPT 4172/4885ALDH1A1 779/4885 |
| US-20180051013-A1 | Heterocyclic Compounds and Methods of Use | HRAS, VHL, ESRRB | AOC3 3646/4885MAPT 4672/4885ALDH1A1 2384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.